Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets.

Outcome Assessment, Health Care Patient Reported Outcome Measures Systemic Sclerosis

Journal

RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038

Informations de publication

Date de publication:
12 Jan 2024
Historique:
received: 09 04 2023
accepted: 15 07 2023
medline: 13 1 2024
pubmed: 13 1 2024
entrez: 12 1 2024
Statut: epublish

Résumé

Hand involvement is an early manifestation of systemic sclerosis (SSc), culprit of diagnosis and classification, and recognised major driver of disability. Impairment of hand function burdens both limited and diffuse cutaneous subsets and therefore could be targeted as 'basket' endpoint in SSc. Nevertheless, its natural history in current standard of care is not well characterised, limiting the design of targeted trials. The aim of this study is to describe prevalence, natural history and clinical factors associated with hand function deterioration in a longitudinal, multicentre, observational SSc cohort. Hand function was captured through the validated Cochin Hand Function Scale in patients consecutively enrolled in a multicentre observational study and observed over 24 months. Minimal clinically important differences and patient acceptable symptom state were analysed as previously described. Three hundred and ninety-six consecutive patients were enrolled from 10 centres; 201 with complete follow-up data were included in the analysis. Median (IQR) disease duration was 5 (2-11) years. One hundred and five (52.2%) patients reported clinically significant worsening. Accordingly, the proportion of patients reporting unacceptable hand function increased over 2 years from 27.8% to 35.8% (p<0.001). Least absolute shrinkage and selection operator analysis identified male gender, disease subset, Raynaud's Condition Score, tenosynovitis and pain, as some of the key factors associated with worsening hand involvement. Hand function deteriorates over time in more than 50% of SSc patients despite available therapies. The analysis of factors associated with hand function worsening supports the involvement of both inflammation, vascular and fibrotic processes in hand involvement, making it a hallmark clinical manifestation of SSc. Our data are poised to inform the design of intervention studies to target this major driver of disability in SSc.

Sections du résumé

BACKGROUND BACKGROUND
Hand involvement is an early manifestation of systemic sclerosis (SSc), culprit of diagnosis and classification, and recognised major driver of disability. Impairment of hand function burdens both limited and diffuse cutaneous subsets and therefore could be targeted as 'basket' endpoint in SSc. Nevertheless, its natural history in current standard of care is not well characterised, limiting the design of targeted trials. The aim of this study is to describe prevalence, natural history and clinical factors associated with hand function deterioration in a longitudinal, multicentre, observational SSc cohort.
METHODS METHODS
Hand function was captured through the validated Cochin Hand Function Scale in patients consecutively enrolled in a multicentre observational study and observed over 24 months. Minimal clinically important differences and patient acceptable symptom state were analysed as previously described.
RESULTS RESULTS
Three hundred and ninety-six consecutive patients were enrolled from 10 centres; 201 with complete follow-up data were included in the analysis. Median (IQR) disease duration was 5 (2-11) years. One hundred and five (52.2%) patients reported clinically significant worsening. Accordingly, the proportion of patients reporting unacceptable hand function increased over 2 years from 27.8% to 35.8% (p<0.001). Least absolute shrinkage and selection operator analysis identified male gender, disease subset, Raynaud's Condition Score, tenosynovitis and pain, as some of the key factors associated with worsening hand involvement.
CONCLUSIONS CONCLUSIONS
Hand function deteriorates over time in more than 50% of SSc patients despite available therapies. The analysis of factors associated with hand function worsening supports the involvement of both inflammation, vascular and fibrotic processes in hand involvement, making it a hallmark clinical manifestation of SSc. Our data are poised to inform the design of intervention studies to target this major driver of disability in SSc.

Identifiants

pubmed: 38216288
pii: rmdopen-2023-003216
doi: 10.1136/rmdopen-2023-003216
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: Direct or indirect interests that might affect or be perceived to affect the conduct or reporting of this work. EDL: nothing to declare, VK; nothing to declare, SDD: nothing to declare, MW: nothing to declare, TB: nothing to declare, CPD: nothing to declare, EDS: nothing to declare, KD: nothing to declare, PW: nothing to declare, AH: nothing to declare, BS: nothing to declare, MN: nothing to declare, CM: nothing to declare, LG: nothing to declare, BAP: nothing to declare, FDG: nothing to declare.

Auteurs

Enrico De Lorenzis (E)

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Division of Rheumatology, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.

Vishal Kakkar (V)

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Stefano Di Donato (S)

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.

Michelle Wilson (M)

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.

Theresa Barnes (T)

Department of Rheumatology, Countess of Chester Hospital NHS Foundation Trust, Liverpool, UK.

Chris Denton (C)

Department of Rheumatology, Royal Free London NHS Foundation Trust, London, UK.

Emma Derrett-Smith (E)

Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Karen Douglas (K)

Department of Rheumatology, The Dudley Group NHS Foundation Trust, Dudley, UK.

Philip Helliwell (P)

Department of Rheumatology, St. Luke's Hospital, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.

Ariane L Herrick (AL)

Centre for Musculoskeletal Research, The University of Manchester, Salford Royal NHS Foundation Trust,Manchester Academic Health Science Centre, Manchester, UK.

Benazir Saleem (B)

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Department of Rheumatology, York Teaching Hospital NHS Foundation Trust, York, UK.

Muhammad Nisar (M)

Department of Rheumatology, Luton & Dunstable University Hospital NHS Foundation Trust, Luton, UK.

Catherine Morley (C)

Department of Rheumatology, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.

Lorraine Green (L)

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Begonya Alcacer-Pitarch (B)

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Francesco Del Galdo (F)

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK f.delgaldo@leeds.ac.uk.
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Classifications MeSH